Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sinovac Biotech's Days Inventory or its related term are showing as below:
SVA'
s Days Inventory Range Over the Past 10 Years
Min: 81.92 Med: 300.8 Max: 398.41
Current: 297.58
During the past 13 years, Sinovac Biotech's highest Days Inventory was 398.41. The lowest was 81.92. And the median was 300.80.
SVA's Days Inventory is not ranked
in the Biotechnology industry.
Industry Median: 183.75
vs SVA: 297.58
Sinovac Biotech's Days Inventory
declined
from Jun. 2025 (385.24) to Jun. 2026 (355.70).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sinovac Biotech's Inventory Turnover for the
six
months ended in Jun. 2026 was 0.51.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sinovac Biotech's Inventory-to-Revenue for the
six
months ended in Jun. 2026 was 0.68.
Sinovac Biotech (NAS:SVA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sinovac Biotech's Inventory Turnover for the
six
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sinovac Biotech's Inventory to Revenue for the
six
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sinovac Biotech Days Inventory Related Terms
Sinovac Biotech Days Inventory Historical Data
* Premium members only.
The historical data trend for Sinovac Biotech's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sinovac Biotech's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinovac Biotech Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sinovac Biotech's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinovac Biotech (SVA) has a Days Inventory of 355.70 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sinovac Biotech and its competitors. This is 18% above median its historical median of 300.80. Over the past decade, Sinovac Biotech's Days Inventory has ranged from 81.92 to 398.41.
Is Sinovac Biotech's Days Inventory too high?
Sinovac Biotech's current Days Inventory of 355.70 is 18% above median its 10-year median of 300.80. Over the past 10 years, this metric has ranged from a low of 81.92 to a high of 398.41. The Biotechnology industry median Days Inventory is 183.75. Sinovac Biotech's value of 355.70 is 93.6% above this industry median. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's Days Inventory compare to INBX and HLVX?
Sinovac Biotech's Days Inventory of 355.70 can be compared against companies in the Biotechnology industry. The industry median Days Inventory is 183.75. Sinovac Biotech's value of 355.70 is 93.6% above this benchmark. Historically, Sinovac Biotech's own Days Inventory has ranged from 81.92 to 398.41 over the past decade. While the company's 10-year median is 300.80 vs. the industry median of 183.75, Sinovac Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.75, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinovac Biotech's current Days Inventory of 355.70 is 93.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sinovac Biotech and its competitors. For the Biotechnology industry, the median Days Inventory is 183.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinovac Biotech's current Days Inventory is 355.70, which is 18% above median its own 10-year median of 300.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (SVA) has a current Days Inventory of 355.70. The current Days Inventory is 355.70, which is 18% above median its 10-year median of 300.80 and 93.6% above the Biotechnology industry median of 183.75. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sinovac Biotech (SVA), the current Days Inventory is 355.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score
Get the complete analysis for SVA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SVA has been successfully added to your 
